or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.carvedilolMonitor Closely (1)terazosin and carvedilol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.celecoxibMonitor Closely (1)celecoxib decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.celiprololMonitor Closely (1)terazosin and celiprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.choline magnesium trisalicylateMonitor Closely (1)choline magnesium trisalicylate decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.clevidipineMonitor Closely (1)terazosin and clevidipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.diclofenacMonitor Closely (1)diclofenac decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.diflunisalMonitor Closely (1)diflunisal decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.diltiazemMonitor Closely (1)terazosin and diltiazem both increase anti-hypertensive channel blocking. Use Caution/Monitor.doxazosinMonitor Closely (1)doxazosin and terazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.enalaprilMonitor Closely (1)enalapril, terazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.esmololMonitor Closely (1)terazosin and esmolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Additive hypotensive effects may occur when terazosin is used in combination with esmolol.ethanolMinor (1)terazosin, ethanol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension, esp. in Asian pts.etodolacMonitor Closely (1)etodolac decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.felodipineMonitor Closely (1)terazosin and felodipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.fenoprofenMonitor Closely (1)fenoprofen decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.flurbiprofenMonitor Closely (1)flurbiprofen decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.fosinoprilMonitor Closely (1)fosinopril, terazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.ibuprofenMonitor Closely (1)ibuprofen decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ibuprofen IVMonitor Closely (1)ibuprofen IV decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.iloperidoneMonitor Closely (1)iloperidone increases effects of terazosin by pharmacodynamic synergism. Use Caution/Monitor.imidaprilMonitor Closely (1)imidapril, terazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.indomethacinMonitor Closely (1)indomethacin decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.isradipineMonitor Closely (1)terazosin and isradipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.ketoprofenMonitor Closely (1)ketoprofen decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ketorolacMonitor Closely (1)ketorolac decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.ketorolac intranasalMonitor Closely (1)ketorolac intranasal decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.labetalolMonitor Closely (1)terazosin and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.levodopaMonitor Closely (1)levodopa increases effects of terazosin by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.lisinoprilMonitor Closely (1)lisinopril, terazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.lofexidineSerious - Use Alternative (1)lofexidine, terazosin. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension.lornoxicamMonitor Closely (1)lornoxicam decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.lurasidoneMonitor Closely (1)lurasidone increases effects of terazosin by Other (see comment). Use Caution/Monitor. Comment: Potential for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust dose of antihypertensive agent as needed.maravirocMonitor Closely (1)maraviroc, terazosin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.meclofenamateMonitor Closely (1)meclofenamate decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.mefenamic acidMonitor Closely (1)mefenamic acid decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.meloxicamMonitor Closely (1)meloxicam decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.methylphenidateMonitor Closely (1)methylphenidate will decrease the level or effect of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP.metoprololMonitor Closely (1)terazosin and metoprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.moexiprilMonitor Closely (1)moexipril, terazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.moxisylyteMonitor Closely (1)moxisylyte and terazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.nabumetoneMonitor Closely (1)nabumetone decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.nadololMonitor Closely (1)terazosin and nadolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.naproxenMonitor Closely (1)naproxen decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.nebivololMonitor Closely (1)terazosin and nebivolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.nicardipineMonitor Closely (1)terazosin and nicardipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.nifedipineMonitor Closely (1)terazosin and nifedipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.nisoldipineMonitor Closely (1)terazosin and nisoldipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.nitroglycerin rectalMonitor Closely (1)nitroglycerin rectal, terazosin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .oxaprozinMonitor Closely (1)oxaprozin decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.oxymetazoline topicalMonitor Closely (1)oxymetazoline topical increases and terazosin decreases sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Effect of interaction is not clear, use caution. Use Caution/Monitor.parecoxibMonitor Closely (1)parecoxib decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.penbutololMonitor Closely (1)terazosin and penbutolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.perindoprilMonitor Closely (1)perindopril, terazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.phenoxybenzamineMonitor Closely (1)phenoxybenzamine and terazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.phentolamineMonitor Closely (1)phentolamine and terazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.phenylephrineMinor (1)terazosin, phenylephrine. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.phenylephrine POMinor (1)terazosin, phenylephrine PO. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.pindololMonitor Closely (1)terazosin and pindolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.piroxicamMonitor Closely (1)piroxicam decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.prazosinMonitor Closely (1)prazosin and terazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.propranololMonitor Closely (1)terazosin and propranolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Additive hypotensive effects may occur when terazosin is used in combination with propranolol.pseudoephedrineMonitor Closely (1)pseudoephedrine decreases effects of terazosin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.quinaprilMonitor Closely (1)quinapril, terazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.ramiprilMonitor Closely (1)ramipril, terazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.salicylates (non-asa)Monitor Closely (1)salicylates (non-asa) decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.salsalateMonitor Closely (1)salsalate decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.sildenafilSerious - Use Alternative (1)sildenafil increases effects of terazosin by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of hypotension; separate sildenafil >25mg from alpha blocker by 4hr.silodosinMonitor Closely (1)silodosin and terazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.sotalolMonitor Closely (1)terazosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. Additive hypotensive effects may occur when terazosin is used in combination with sotalol.sulfasalazineMonitor Closely (1)sulfasalazine decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.sulindacMonitor Closely (1)sulindac decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.tadalafilMonitor Closely (1)tadalafil increases effects of terazosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.tamsulosinSerious - Use Alternative (1)terazosin, tamsulosin. Either increases effects of the other by additive vasodilation. Avoid or Use Alternate Drug. Risk of hypotension.timololMonitor Closely (1)terazosin and timolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.tizanidineMinor (1)tizanidine increases effects of terazosin by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.tolfenamic acidMonitor Closely (1)tolfenamic acid decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.tolmetinMonitor Closely (1)tolmetin decreases effects of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.trandolaprilMonitor Closely (1)trandolapril, terazosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.treprostinilMinor (1)treprostinil increases effects of terazosin by pharmacodynamic synergism. Minor/Significance Unknown.vardenafilSerious - Use Alternative (1)vardenafil increases effects of terazosin by pharmacodynamic synergism. Contraindicated. Risk of hypotension.verapamilMonitor Closely (1)terazosin and verapamil both increase anti-hypertensive channel blocking. Use Caution/Monitor.yohimbeSerious - Use Alternative (1)yohimbe increases effects of terazosin by pharmacodynamic synergism. Contraindicated.zotepineMonitor Closely (1)terazosin and zotepine both increase anti-hypertensive channel blocking. Use Caution/Monitor. >10% Dizziness (10-20%) Asthenia (2-13%) 1-10% Hypotension (3-7%) Rhinitis/nasal congestion (2-6%) Lightheadedness (3-5%) Somnolence (3-5%) Palpitation (4%) Nausea (2-4%) Edema (3%) Sinusitis (3%) Dyspnea (2-3%) Fatigue (2.5%) Headache (2.5%) Back pain (2.4%) Flulike syndrome (2.4%) Tachycardia (2%) Amblyopia (1-2%) Blurred vision (1-2%) Impotence (1-2%) Syncope (1%) Contraindications Hypersensitivity to terazosin, other quinazolines Cautions Carcinoma of the prostate and BPH cause many of the same symptoms; these two diseases frequently co-exist; patients thought to have BPH should be examined prior to starting therapy to rule out presence of carcinoma of the prostate Therapy can cause marked lowering of blood pressure, especially postural hypotension, and syncope in association with first dose or first few days of therapy; a similar effect can be anticipated if therapy is interrupted for several days and then restarted; to decrease likelihood of syncope or excessive hypotension, treatment should always be initiated at a low dose (1 mg) and increased slowly; additional antihypertensive agents should be added with caution; patient should be cautioned to avoid situations, such as driving or hazardous tasks, where injury could result should syncope occur during initiation of therapy If syncope occurs, the patient should be placed in a recumbent position and treated supportively as necessary; there is evidence that orthostatic effect is greater, even in chronic use, shortly after dosing; the risk of the events is greatest during initial seven days of treatment, but continues at all time intervals While syncope is the most severe orthostatic effect, other symptoms of lowered blood pressure, such as dizziness, lightheadedness and palpitations, are more common; patients with occupations in which such events represent potential problems should be treated with particular caution May cause CNS depression, which may impair physical or mental abilities; use caution when performing tasks that may require mental alertness, including driving or operating heavy machinery May exacerbate heart failure Concomitant administration with PDE-5 inhibitor (eg, sildenafil) can result in additive blood pressure-lowering effects and symptomatic hypotension; initiate PDE-5 inhibitor therapy at lowest dose Risk of priapism (rare); because this condition can lead to permanent impotence if not promptly treated, patients must be advised about seriousness of the condition Pregnancy category: C Lactation: Not known if excreted into breast milk; use cautionPregnancy Categories A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk. B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available. Mechanism of Action Blocks postsynaptic alpha-1 receptor; alpha blockade causes arterial and venous dilation Selective agents cause less tachycardia than do nonselective agents Absorption Bioavailability: 90% Onset (hypertension): 3 hr Onset (benign prostate hyperplasia): 2 weeks Duration: 24 hr Peak response (benign prostate hyperplasia): 4-6 weeks Peak plasma time: 1 hr Distribution Protein bound: 90-94% Vd: 25-30 L Metabolism Metabolized extensively via hydrolysis, O-demethylation, and N-dealkylation in liver Metabolites: 6- and 7-O-demethyl terazosin, piperazine derivative, diamine metabolite Elimination Half-life: 9-12 hr Renal clearance: 9-12.5 mL/min Excretion: Feces (55-60%); urine (40%) BRAND FORM. UNIT PRICE PILL IMAGE terazosin oral- 5 mg capsuleterazosin oral- 2 mg capsuleterazosin oral- 10 mg capsuleterazosin oral- 1 mg capsuleterazosin oral- 5 mg capsuleterazosin oral- 5 mg capsuleterazosin oral- 2 mg capsuleterazosin oral- 1 mg capsuleterazosin oral- 5 mg capsuleterazosin oral- 1 mg capsuleterazosin oral- 10 mg capsuleterazosin oral- 10 mg capsuleterazosin oral- 10 mg capsuleterazosin oral- 2 mg capsuleterazosin oral- 1 mg capsuleterazosin oral- 2 mg capsuleterazosin oral- 10 mg capsuleCopyright © 2010 First DataBank, Inc.Print Patient Educationterazosin oral TERAZOSIN - ORAL (ter-AY-zoe-sin) COMMON BRAND NAME(S): Hytrin USES: Terazosin is used alone or with other drugs to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication works by relaxing blood vessels so blood can flow more easily.Terazosin is also used in men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and part of the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night).Terazosin belongs to a